TECHNOLOGY:  

Calpain Inhibitors as CW Countermeasures for Halogen and Acid Exposure Injuries

AFFILIATION:   Phelix Therapeutics LLC, Philadelphia, Pennsylvania, United States

TECHNOLOGY SUMMARY

Track: Medical & Biotech
Area: CBRN (Chem/Bio/Rad/Nuclear)
Tech Readiness: TRL 4

Tech Brief: Halogen exposure via CW's or industrial inhalation is a major mortality risk. No drugs currently exist to treat halogen exposure. Phelix's calpain inhibitors block chlorine-induced cell death in human cardiomyocytes and lung epithelial cells, and are part of a broader countermeasures platform against acidic CW agents.

FIGURES OF MERIT

Value Proposition: N/A

SHOWCASE SUMMARY

Org Type: Early-stage Startup (Seed)
Website: http://www.phelixtherapeutics.com
Booth Number: 807